4.8 Article

Lecanemab in Early Alzheimer's Disease

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Clinical Neurology

Lecanemab, Aducanumab, and Gantenerumab - Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's Disease

Linda Soderberg et al.

Summary: Immunotherapy targeting amyloid-beta (A ss) shows promise in treating Alzheimer's disease (AD). This study characterized the binding properties of three antibodies (lecanemab, aducanumab, and gantenerumab) to various A ss species and found different binding preferences, which may explain the variability in clinical efficacy and side effects observed for these antibodies.

NEUROTHERAPEUTICS (2023)

Article Clinical Neurology

Lecanemab, Aducanumab, and Gantenerumab - Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's Disease

Linda Soderberg et al.

Summary: The study revealed different binding profiles of lecanemab, aducanumab, and gantenerumab to various species of Aβ, which may explain the varying clinical outcomes and side effects observed for these antibodies.

NEUROTHERAPEUTICS (2023)

Article Medicine, General & Internal

Donanemab in Early Alzheimer's Disease

Mark A. Mintun et al.

Summary: In this study, donanemab showed improved composite scores for cognition and daily living activities compared to placebo in patients with early Alzheimer's disease at 76 weeks, although secondary outcomes varied. Longer and larger trials are needed to further explore the efficacy and safety of donanemab in Alzheimer's disease.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Article Clinical Neurology

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody

Chad J. Swanson et al.

Summary: BAN2401-G000-201 trial aimed to establish the effective dose and observe the treatment effect. While not meeting the primary endpoint at 12 months, results at 18 months demonstrated reduction in brain amyloid and improvement across multiple clinical and biomarker endpoints.

ALZHEIMERS RESEARCH & THERAPY (2021)

Review Cell Biology

Effects of monoclonal antibodies against amyloid-β on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer's disease

Konstantinos Avgerinos et al.

Summary: Monoclonal antibodies targeting A beta have shown small clinical improvements and large biomarker improvements in Alzheimer's disease patients. However, they also increase the risk of adverse events such as ARIA.

AGEING RESEARCH REVIEWS (2021)

Review Biochemistry & Molecular Biology

The Amyloid-β Pathway in Alzheimer's Disease

Harald Hampel et al.

Summary: Breakthroughs in molecular medicine have highlighted the significance of the amyloid-beta pathway in the pathophysiology of Alzheimer's disease. Established biochemical alterations of the A beta cycle serve as promising targets for the development of disease-modifying therapies. Research indicates a crucial role of A beta pathway dyshomeostasis in the dynamics of AD pathophysiology, supporting the development of A beta-targeting therapeutic strategies for early treatment of AD.

MOLECULAR PSYCHIATRY (2021)

Article Psychiatry

The need to show minimum clinically important differences in Alzheimer's disease trials

Kathy Y. Liu et al.

Summary: Deciding on the smallest change in an outcome that constitutes a clinically meaningful treatment effect is crucial in interpreting clinical trial outcomes and designing studies. While there is no consensus on MCIDs in Alzheimer's disease trials, it is important to incorporate them into clinical trials and drug development guidance.

LANCET PSYCHIATRY (2021)

Article Clinical Neurology

Determining clinically meaningful decline in preclinical Alzheimer disease

Philip S. Insel et al.

NEUROLOGY (2019)

Review Biochemistry & Molecular Biology

Alzheimer Disease: An Update on Pathobiology and Treatment Strategies

Justin M. Long et al.

Article Clinical Neurology

ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials

Jinping Wang et al.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2016)

Article Neurosciences

Specific Uptake of an Amyloid-β Protofibril-Binding Antibody-Tracer in AβPP Transgenic Mouse Brain

Kristina Magnusson et al.

JOURNAL OF ALZHEIMERS DISEASE (2013)

Article Multidisciplinary Sciences

Polymorphic Structures of Alzheimer's β-Amyloid Globulomers

Xiang Yu et al.

PLOS ONE (2011)

Article Neurosciences

Amyloid β-Protein Dimers Rapidly Form Stable Synaptotoxic Protofibrils

Brian O'Nuallain et al.

JOURNAL OF NEUROSCIENCE (2010)

Article Medicine, General & Internal

Amyloid-beta Oligomers: Possible Roles as Key Neurotoxins in Alzheimer's Disease

Alex L. Lublin et al.

MOUNT SINAI JOURNAL OF MEDICINE (2010)

Review Cell Biology

Soluble protein oligomers in neurodegeneration:: lessons from the Alzheimer's amyloid β-peptide

Christian Haass et al.

NATURE REVIEWS MOLECULAR CELL BIOLOGY (2007)